{"id":"sct800-and-daratumumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SCT800 functions as a T-cell engager (BiTE) that bridges cytotoxic T lymphocytes to CD19-expressing B-cell malignancies, enhancing T-cell activation and tumor cell lysis. Daratumumab binds CD38, a surface antigen highly expressed on multiple myeloma cells and other hematologic malignancies, triggering antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. The combination leverages complementary mechanisms to target plasma cell dyscrasias and B-cell malignancies.","oneSentence":"SCT800 is a bispecific antibody that simultaneously engages CD19 on B cells and CD3 on T cells to redirect T-cell killing of CD19+ malignant cells, while daratumumab is a monoclonal antibody targeting CD38 on plasma cells to induce their apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:08.510Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in combination)"},{"name":"B-cell non-Hodgkin lymphoma (SCT800 component)"}]},"trialDetails":[{"nctId":"NCT05888870","phase":"PHASE4","title":"ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-11-22","conditions":"Hemophilia A With Inhibitor","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immune tolerance induction combine anti-CD38"],"phase":"marketed","status":"active","brandName":"SCT800 and Daratumumab","genericName":"SCT800 and Daratumumab","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SCT800 is a treatment being studied for Hemophilia A With Inhibitor, and it is being investigated alone or in combination with Daratumumab in a clinical trial. Daratumumab is an antibody, specifically a monoclonal antibody, used in the treatment of various conditions, including Hemophilia A With Inhibitor in this clinical trial.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}